Novel patient cell-based HTS assay for identification of small molecules for a lysosomal storage disease.
Small molecules have been identified as potential therapeutic agents for lysosomal storage diseases (LSDs), inherited metabolic disorders caused by defects in proteins that result in lysosome dysfunctional. Some small molecules function assisting the folding of mutant misfolded lysosomal enzymes tha...
Main Authors: | Haifeng Geng, Grace Whiteley, Jameson Ribbens, Wei Zheng, Noel Southall, Xin Hu, Juan J Marugan, Marc Ferrer, Gustavo H B Maegawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3244463?pdf=render |
Similar Items
-
Juvenile GM2 Gangliosidosis: A Model for Investigation of Small-molecule Therapies for Lysosomal Storage Diseases
by: Maegawa, Gustavo Henrique Boff
Published: (2008) -
Juvenile GM2 Gangliosidosis: A Model for Investigation of Small-molecule Therapies for Lysosomal Storage Diseases
by: Maegawa, Gustavo Henrique Boff
Published: (2008) -
CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges
by: Mariola J. Edelmann, et al.
Published: (2020-11-01) -
A high throughput screening assay system for the identification of small molecule inhibitors of gsp.
by: Nisan Bhattacharyya, et al.
Published: (2014-01-01) -
The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases
by: James A. Shayman, et al.
Published: (2014-07-01)